Exosome Therapy for Osteoarthritis

Exosomes are extracellular vesicles, not cells. No generic “exosome therapy” label identifies the source, manufacturing controls, contents, sterility, dose or legal status of a proposed product.

Preclinical findings do not prove that an injected product relieves osteoarthritis or regenerates human cartilage. Product heterogeneity makes broad claims especially unreliable.

A person with osteoarthritis should first have the diagnosis, severity, function, conservative care and surgical thresholds reviewed. Interest in an experimental product does not remove the need for evidence-based options.

Exosomes are not stem cells, PRP, hyaluronic acid or a licensed knee gel. The terms must not be blended into one regenerative package.

Request manufacturer, source material, batch testing, sterility, dose, administration route, Malaysian regulatory status, human evidence for the exact product and the plan for serious adverse events.

Discuss infection, contamination, immune or inflammatory reactions, procedure risks and important unknowns. Serious pain, swelling, fever or systemic symptoms need prompt medical evaluation.

Singapore visitors need complete product and treatment records and a cross-border escalation plan. A remote message is not sufficient for potentially serious post-injection symptoms.

No. The reference images support a discussion of the exact exosome product, route, evidence and regulatory status. They are not clinic-patient photographs, proof of stock or a prediction of benefit. Predefine pain and function measures and document every other treatment. Do not use a change in lighting, a single scan slice or testimonials as proof of cartilage regeneration.